Cue Biopharma (NASDAQ:CUE) Shares Gap Down – Should You Sell?

Shares of Cue Biopharma, Inc. (NASDAQ:CUE) gapped down before the market opened on Friday . The stock had previously closed at $16.6260, but opened at $11.06. Cue Biopharma shares last traded at $15.5140, with a volume of 90,443 shares.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CUE. Wall Street Zen raised Cue Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Cue Biopharma in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Cue Biopharma Stock Performance

The business’s 50 day moving average price is $10.25 and its 200-day moving average price is $13.51. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -55.30 and a beta of 1.57.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings results on Monday, March 16th. The company reported $0.30 EPS for the quarter. The business had revenue of $21.94 million during the quarter. Cue Biopharma had a negative return on equity of 165.19% and a negative net margin of 96.85%.

Institutional Investors Weigh In On Cue Biopharma

A number of institutional investors have recently made changes to their positions in the company. Stifel Financial Corp raised its position in shares of Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after acquiring an additional 50,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after purchasing an additional 73,000 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Cue Biopharma in the third quarter worth $62,000. Boothbay Fund Management LLC boosted its holdings in Cue Biopharma by 15.3% in the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc increased its stake in Cue Biopharma by 1,231.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after purchasing an additional 407,568 shares during the last quarter. 35.04% of the stock is currently owned by institutional investors.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.